The Effect of Esketamine on Postoperative Pain Relief in Patients Undergoing Laparoscopic Surgery
The Effect of Low-dose Ketamine on Postoperative Pain Relief and Sleep Quality in Patients Undergoing Laparoscopic Uterine Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Ma Hanxiang
- Phone Number: 86-13519591508
- Email: mahanxiang@hotmail.com
Study Locations
-
-
Ningxia
-
Yinchuan, Ningxia, China
- General Hospital of Ningxia Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient Undergoing laparoscopic uterine surgery under general anesthesia (total hysterectomy, myomectomy);
- Patients gave the informed consent and signed the informed consent form.
- The ASA is Ⅰ-Ⅱ
Exclusion Criteria:
- Patients allergic to anesthetics, ropivacaine, and esketamine or with contraindications to use;
- Patients with cognitive dysfunction or an inability to communicate;
- Transfer to the ICU after surgery;
- Patients with hyperthyroidism, tachyarrhythmia, or severe hypertension;
- Unwilling to use PCIA or refuse to participate in this trial;
- Patients with liver and kidney dysfunction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Group C(Control Group)
At the beginning of the operation, intravenous infusion of reifentanil 0.1~0.2
μg/kg·min, propofol 2~4mg/kg·h, rocuronium 0.3mg/kg·h intermittently, inhalation of 1%~2% sevoflurane were maintained, the fluctuation of blood pressure was not more than 20% of the basic level, and the heart rate was 50~100 times /min.
Pump proper amount of normal saline.The postoperative PCIA regimen was Sufentanil 2ug/kg, ondansetron 16mg, diluted with appropriate normal saline, a total of 100ml
|
A maintenance dose of saline is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondansetron 16mg, diluted with appropriate normal saline, a total of 100ml
Other Names:
|
|
Experimental: Group K(Esketamine Group)
Intraoperatively, remifentanil 0.1-0.2
μg/kg·min, propofol 2-4 mg/kg·h, intermittent rocuronium 0.3 mg/kg·h, inhalation of 1%-2% sevoflurane were given by continuous intravenous infusion, to maintain blood pressure fluctuation within 20% of the baseline level and heart rate within 50-100 beats/min.
Esketamine 0.2mg/kg·h was pumped at the beginning of the procedure.The postoperative PCIA regimen was Sufentanil 2ug/kg, ondanseetron 16mg, esketamine 0.75mg/kg, diluted with appropriate normal saline, a total of 100ml.
|
A maintenance dose of esketamine is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondanseetron 16mg, esketamine 0.75mg/kg, diluted with appropriate normal saline, a total of 100ml
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Moderate to severe pain
Time Frame: 2 hours, 4 hours, 8 hours, 12 hours, 24 hours after surgery
|
Pain severity was measured using The NRS((Numerical Rating Scale), The NRS>3 was considered moderate to severe pain.The NRS score at 2 hours, 4 hours, 8 hours, 12hours, 24hours after surgery was observed to determine whether intraoperative infusion of esketamine combined with perioperative analgesia regimen of esketamine in postoperative PCIA could reduce the incidence of postoperative moderate to severe pain in patients undergoing gynecological laparoscopic uterine surgeryesketamine to postoperative PCIA can reduce the incidence of postoperative moderate to severe pain in patients undergoing laparoscopic uterine surgery under general anesthesia
|
2 hours, 4 hours, 8 hours, 12 hours, 24 hours after surgery
|
|
Incidence of adverse reactions including nausea, vomiting and dizziness
Time Frame: Within 48 hours after surgery
|
Postoperative nausea, vomiting and dizziness is the subjective discomfort of dizziness, nausea, vomiting after the patient is awake, and the diagnosis can be made according to the clinical manifestations of the patient after surgery.
Incidence of adverse reactions including nausea, vomiting and dizziness within 48 hours after surgery.
|
Within 48 hours after surgery
|
|
Sleep quality
Time Frame: the first and second night after surgery
|
Sleep quality scores on the first and second night after surgery was assessed by AIS((Athens Insomnia Scale).The AIS<4 was classified as no sleep disorder, AIS of 4 to 6 is classified as suspicious insomnia, AIS>6 is classified as insomnia.
|
the first and second night after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Remifentanil dosage
Time Frame: During surgery
|
The total amount of remifentanil used during surgery
|
During surgery
|
|
Additional post-operative analgesics
Time Frame: Within 48 hours after surgery
|
The total amount of additional analgesics used after surgery (oral versus intramuscular)
|
Within 48 hours after surgery
|
|
Postoperative exhaust time of patients
Time Frame: Within three days after surgery
|
How long does the patient recover bowel motility after surgery
|
Within three days after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Ran Gao-2023-12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.